These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 31036011)

  • 1. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey.
    Yi S; Mun P; Chhoun P; Chann N; Tuot S; Mburu G
    Harm Reduct J; 2019 Apr; 16(1):29. PubMed ID: 31036011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and risk factors of HIV infection among people who inject drugs in Cambodia: findings from a national survey.
    Mburu G; Chhoun P; Chann N; Tuot S; Mun P; Yi S
    Subst Abuse Treat Prev Policy; 2019 Oct; 14(1):42. PubMed ID: 31623645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and correlates of HIV infection among people who use drugs in Cambodia: a cross-sectional survey using respondent driven sampling method.
    Tuot S; Mburu G; Mun P; Chhoun P; Chann N; Prem K; Yi S
    BMC Infect Dis; 2019 Jun; 19(1):515. PubMed ID: 31185925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors associated with HIV and hepatitis C virus co-infection among people who inject drugs in Cambodia.
    Saing CH; Prem K; Uk P; Chhoun P; Chann N; Tuot S; Mun P; Yi S
    Int J Drug Policy; 2020 Oct; 86():102974. PubMed ID: 33068831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
    Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
    BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
    Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
    Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar.
    Khatib A; Matiko E; Khalid F; Welty S; Ali A; Othman A; Haji S; Dahoma M; Rutherford G
    BMC Public Health; 2017 Nov; 17(1):917. PubMed ID: 29183287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
    Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ
    J Hepatol; 2021 Feb; 74(2):293-302. PubMed ID: 32931879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.
    McFall AM; Solomon SS; Lucas GM; Celentano DD; Srikrishnan AK; Kumar MS; Mehta SH
    Addiction; 2017 Aug; 112(8):1480-1487. PubMed ID: 28317210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
    Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
    Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India.
    Clipman SJ; Mehta SH; Srikrishnan AK; Zook KJ; Duggal P; Mohapatra S; Shanmugam S; Nandagopal P; Kumar MS; Ogburn E; Lucas GM; Latkin CA; Solomon SS
    Elife; 2021 Aug; 10():. PubMed ID: 34342266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of HIV/Hepatitis C Virus Co-Infection and Injection Risk Correlations in People Who Inject Drugs in Colombia: A Cross-Sectional Study Using Respondent Driven Sampling.
    Toro-Tobón D; Berbesi-Fernández D
    Subst Use Misuse; 2020; 55(3):414-423. PubMed ID: 31691646
    [No Abstract]   [Full Text] [Related]  

  • 16. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs.
    Prouté M; Le Coeur S; Tiv MH; Dub T; Jongpaijitsakul P; Ratnamhin A; Angkurawaranon C; Aramrattana A; Lallemant M
    BMC Public Health; 2020 Sep; 20(1):1450. PubMed ID: 32972359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania.
    Lambdin BH; Lorvick J; Mbwambo JK; Rwegasha J; Hassan S; Lum P; Kral AH
    Int J Drug Policy; 2017 Jul; 45():64-69. PubMed ID: 28628854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
    Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
    Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis.
    Yuan JM; Croxford S; Viviani L; Emanuel E; Phipps E; Desai M
    Int J Drug Policy; 2022 Nov; 109():103821. PubMed ID: 35994940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.